Niraparib (ZEJULA/GSK) – Guidelines+ Monographs
Ovarian cancer, the 5th leading cause of cancer deaths in the U.S., is one of the deadliest gynecologic malignancies due to its mild early symptoms, often leading to late detection. This edition of our Guidelines+ Monograph series explores niraparib (brand name Zejula) from GlaxoSmithKline (GSK), a once-daily oral (PO) PARP inhibitor. It’s FDA-approved as a […]